

Serial No.: 08/447,118

Group Art Unit: 1600

B1 sub C1
10. (Twice Amended) A method for the treatment of insulin dependent type I diabetes comprising administering to a mammal with a susceptibility to diabetes one or more compositions selected from the group consisting of an antibody, a fragment[s] of such antibody[ies,] ^{SAID} and a soluble VCAM-1 polypeptide[s and fibronectin polypeptides] capable of binding to the α_4 subunit of VLA-4, in an amount effective to treat diabetes.

B2 sub C3
16. (Twice Amended) A method according to claim 10, wherein the composition is administered at a dosage so as to provide from about 0.1 to about 10 mg/kg of antibody[,] or antibody fragment, based on the weight of the susceptible mammal.

sub C5 B3
25. (Amended) A method according to claim 10, wherein the composition comprises an antibody or a fragment[s] of such antibody[ies] capable of binding to the α_4 subunit of VLA-4.

Please cancel claim 27.

REMARKS

Claims 10, 12-18 and 25-29 are pending. Claims 10, 16 and 25 have been amended. Claim 27 has been canceled. No new matter has been added.

Claims 10, 12-18 and 25-29 have been rejected under 35 USC § 112, first paragraph. Claims 10, 12-18 and 25-29 have been rejected under 35 USC § 112, second paragraph. Claims 10 and 15-18 have been rejected for double patenting.

The rejections are addressed below in the order they appear in the Office Action.

Formalities

A newly executed declaration under 37 CFR § 1.67(a) is submitted herewith. Description of Figure 5 was corrected as requested by the Examiner.

Personal Interview

The personal interview conducted between Examiner Ungar, Supervisory Examiner Feisee, Louis Myers and Ivana Maravic-Magovcevic on May 18, 1998, is gratefully acknowledged. Pending claims were discussed during the interview and it was agreed that the specification enables the claims.